Plasma kallikrein inhibitor patent for ocular disorders

The USPTO issued Patent Grant US12589093B2 to BioCryst Pharmaceuticals, Inc. on March 31, 2026, granting exclusive rights to plasma kallikrein inhibitors (including avoralstat) for non-surgical ocular treatments. The patent covers compositions for delivery to the suprachoroidal space of the eye to treat ocular diseases and conditions, with 16 total patent claims. The original application was filed April 8, 2020, under Application No. 17602674.

This patent grant represents a routine intellectual property award and does not impose compliance obligations on other entities. Competing pharmaceutical companies developing similar ophthalmic therapies should be aware of BioCryst's patent claims when designing their R&D programs to avoid potential infringement. No immediate action is required from compliance teams, though patent clearance analyses for ocular drug development programs should account for these claims.